Ipayipi - Sorrento Therapeutics

I-R&D ye-Sorrento igxile ekushayeleni okusha ku-COVID-19, ukwelashwa komdlavuza, ukulawula izinhlungu ngokugcwele kanye nezifo ezizimele.

Izinhlelo Ezibalulekile

Isiboniso

Ukucabangela

Isigaba I

Phase II

Isigaba III/Esibalulekile

Ukugunyazwa kwe-FDA

Izinhlelo ze-COVID-19

COVISTIX™ (ukuxilonga)

Rapid Antigen Test

0%*

Ukugunyazwa Kokusetshenziswa Kwezimo Eziphuthumayo (EUA) e-Mexico (COFEPRIS), Brazil (ANVISA), kanye ne-CE Emakwe eYurophu

I-COVIMARK™ (ukuxilonga)

Rapid Antigen Test

0%*

Isicelo sithunyelwe e-US nase-Canada Sokugunyazwa Ukusetshenziswa Kwezimo Eziphuthumayo (EUA)

COVISHIELD™ (ukwelashwa)

I-Neutralizing Antibody (IN) Ezigulini Ezingaphandle Neziguli Ezilaliswayo

40%*

COVISHIELD™ (ukwelashwa)

I-Neutralizing Antibody (IV) Ezigulini Ezingaphandle Neziguli Ezilaliswayo

20%*

FUJOVEE™ (Abivertinib)

I-COVID-19 enzima ezigulini zase-ICU

82%*

Isivivinyo Esibalulekile Esisalindile I-FDA Clearance

OQORY™ (COVI-MSC)

I-ARDS ngenxa ye-COVID-19 ezigulini zase-ICU

82%*

Isivivinyo Esibalulekile eBrazil

M^Pro Inhibitor (iphilisi lomlomo)

Anti-viral

40%*

Umgomo we-Omicron mRNA

Umgomo

20%*

Izinhlelo Ezibalulekile

Isiboniso

Ukucabangela

Isigaba I

Phase II

Isigaba III/Esibalulekile

Ukugunyazwa kwe-FDA

immunotherapy

FUJOVEE™ (Abivertinib)

I-NSCLC

82%*

FUJOVEE™ (Abivertinib)

I-B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib)

I-Prostate

20%*

FUJOVEE™ (Abivertinib)

Lupus

20%*

FUJOVEE™ (Abivertinib)

20%*

FUJOVEE™ (Abivertinib)

I-GvHD

20%*

I-PD-L1 (Socazolimab)*

I-SCLC

82%*

*Ngokubambisana ne-Lee's Pharm e-China

I-PD-L1 (STI-3031)**

Umdlavuza wesibeletho

82%*

**E-US futhi ngokubambisana ne-ImmuneOncia yaseKorea

I-CD47

Izimila eziqinile

40%*

I-CD38 DAR-T

I-Myeloma eminingi

40%*

CD38 ADC

I-Amyloidosis, i-Myeloma eminingi, i-T-ALL, ne-esophageal

40%*

I-TROP2 ADC*

Izimila eziqinile

40%*

* E-China

I-Seprehvec™ oncolytic virus

Izimila eziqinile; Izicubu ze-CNS

40%*

I-BCMA ADC

Izimila Liquid

20%*

I-Bevacizumab-ADAB™

Umdlavuza we-Endometrial

40%*

Ngokubambisana neMayo Clinic

I-Bevacizumab-ADAB™

Cancer wesibeletho

40%*

Ngokubambisana neMayo Clinic

I-Rituximab-ADAB™

I-B-cell Lymphomas

40%*

Ngokubambisana neMayo Clinic

Izinhlelo Ezibalulekile

Isiboniso

Ukucabangela

Isigaba I

Phase II

Isigaba III/Esibalulekile

Ukugunyazwa kwe-FDA

Ubuhlungu

I-ZTlido™ 1.8%

I-Postherpetic Neuralgia - PHN

99.8%*

I-SP-102 (SEMDEXA)

I-Lumbar Radicular / Sciatica Pain

82%*

I-SP-103 (I-Lidocaine Topical System 5.4%)

Ubuhlungu Obubuhlungu Emuva

20%*

I-SP-104 (I-Naltrexone Yokuqhunyiswa Ebambezelekile)

fibromyalgia

20%*

I-RTX (resiniferatoxin)
Umjovo we-epidural

Ubuhlungu Obungalawuleki Kumdlavuza Othuthukile

60.3%*

Igama lentandane

I-RTX (resiniferatoxin)
Umzila we-Intra-articular

Ubuhlungu Bedolo Obuphakathi Kuya Kunzima

60.2%*

Izinhlelo Ezibalulekile

Isiboniso

Ukucabangela

Isigaba I

Phase II

Isigaba III/Esibalulekile

Ukugunyazwa kwe-FDA

Ukulethwa kwe-Lymphatic

Sofusa^® elwa ne-TNF

I-Autoimmune (RA)

40%*

Sofusa^® i-anti-PD-1

I-Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa^® anti-CTLA-4

I-Melanoma

40%*

Ngokubambisana neMayo Clinic

Izinhlelo ze-COVID-19

Izinhlelo Ezibalulekile (Inkomba)

Isigaba

COVISTIX™ (ukuxilonga)

I-FDA EUA

I-COVIMARK™ (ukuxilonga)

I-FDA EUA

COVISHIELD™ (ukwelashwa)

PH I

COVISHIELD™ (ukwelashwa)

Ukucabangela

FUJOVEE™ (Abivertinib)

Ph III

OQORY™ (COVI-MSC)

Ph III

I-Mpro Inhibitor (iphilisi lomlomo) (anti-viral)

Ph I

Umgomo we-Omicron mRNA (umuthi wokugoma)

Ukucabangela

immunotherapy

Izinhlelo Ezibalulekile (Inkomba)

Isigaba

I-FUJOVEE™ (Abivertinib) (NSCLC)

Ph III

I-FUJOVEE™ (Abivertinib) (B Cell Lymphomas)

Ph II

I-FUJOVEE™ (Abivertinib) (Prostate)

Ukucabangela

I-FUJOVEE™ (Abivertinib) (I-Lupus)

Ukucabangela

I-FUJOVEE™ (Abivertinib) (MS)

Ukucabangela

I-FUJOVEE™ (Abivertinib) (GvHD)

Ukucabangela

I-PD-L1 (Socazolimab)*(SCLC)

Ph III

I-PD-L1 (STI-3031)** (Umdlavuza wesibeletho)

Ph III

I-CD47 (Izimila Eziqinile)

Ph I

I-CD38 DAR-T (I-Myeloma eminingi)

Ph I

CD38 ADC (I-Amyloidosis, i-Myeloma eminingi, i-T-ALL, ne-esophageal)

Ph I

I-TROP2 ADC* (Izimila Eziqinile)

Ph I

I-Seprehvec™ oncolytic virus (Izimila Eziqinile; CNS Tumors)

PH I

I-BCMA ADC (Amathumba Amanzi)

Ukucabangela

I-Bevacizumab-ADAB™ (Umdlavuza we-Endometrial)

Ph I

I-Bevacizumab-ADAB™ (Umdlavuza wesibeletho)

Ph I

I-Rituximab-ADAB™ (B-cell Lymphomas)

Ph I

Ubuhlungu

Izinhlelo Ezibalulekile (Inkomba)

Isigaba

I-ZTlido™ 1.8% (I-Postherpetic Neuralgia - PHN)

Ukugunyazwa kwe-FDA

I-SP-102 (SEMDEXA)

Ph III

I-SP-103 (I-Lidocaine Topical System 5.4%)

Ukucabangela

I-SP-104 (I-Naltrexone Yokuqhunyiswa Ebambezelekile)

Ukucabangela

I-RTX (resiniferatoxin) umjovo we-epidural (Ubuhlungu obungalawuleki kuCancer Osezingeni eliphezulu)

Ph II

I-RTX (resiniferatoxin) Umzila we-intra-articular (Ubuhlungu bedolo obuphakathi ukuya kuye obunzima)

Ph II

Ukulethwa kwe-Lymphatic

Izinhlelo Ezibalulekile (Inkomba)

Phase II

Sofusa^® elwa ne-TNF (I-Autoimmune RA)

Ph I

Sofusa^® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL))

Ph I

Sofusa^® anti-CTLA-4 (I-melanoma)

Ph I